Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Characterization of the clotting activities of structurally different forms of activated factor IX. Enzymatic properties of normal human factor IXa alpha, factor IXa beta, and activated factor IX Chapel Hill.
M J Griffith, … , R L Lundblad, H R Roberts
M J Griffith, … , R L Lundblad, H R Roberts
Published January 1, 1985
Citation Information: J Clin Invest. 1985;75(1):4-10. https://doi.org/10.1172/JCI111694.
View: Text | PDF
Research Article

Characterization of the clotting activities of structurally different forms of activated factor IX. Enzymatic properties of normal human factor IXa alpha, factor IXa beta, and activated factor IX Chapel Hill.

  • Text
  • PDF
Abstract

Two structurally different forms of activated human Factor IX (Factor IXa alpha and IXa beta) have been previously reported to have essentially identical clotting activity in vitro. Although it has been shown that activated Factor IX Chapel Hill, an abnormal Factor IX isolated from the plasma of a patient with mild hemophilia B, and normal Factor IXa alpha are structurally very similar, the clotting activity of activated Factor IX Chapel Hill is much lower (approximately fivefold) than that of normal Factor IXa beta. In the present study we have prepared activated Factor IX by incubating human Factor IX with calcium and Russell's viper venom covalently bound to agarose. Fractionation of the activated Factor IX by high-performance liquid chromatography demonstrated the presence of both Factors IXa alpha and IXa beta. On the basis of active site concentration, determined by titration with antithrombin III, the clotting activities of activated Factor IX Chapel Hill and IXa alpha were similar, but both activities were less than 20% of the clotting activity of Factor IXa beta. Activated Factor IX activity was also measured in the absence of calcium, phospholipid, and Factor VIII, by determination of the rate of Factor X activation in the presence of polylysine. In the presence of polylysine, the rates of Factor X activation by activated Factor IX Chapel Hill, Factor IXa alpha, and Factor IXa beta were essentially identical. We conclude that the clotting activity of activated Factor IX Chapel Hill is reduced when compared with that of Factor IXa beta but essentially normal when compared with that of Factor IXa alpha.

Authors

M J Griffith, L Breitkreutz, H Trapp, E Briet, C M Noyes, R L Lundblad, H R Roberts

×

Total citations by year

Year: 2024 2020 2019 2015 2013 2012 2010 2009 2002 2001 2000 1999 1998 1996 1995 1994 1993 1992 1990 1989 1988 1985 Total
Citations: 1 1 1 1 1 2 3 1 3 2 1 1 3 1 3 3 2 1 6 3 1 1 42
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (42)

Title and authors Publication Year
Blood coagulation factor IX: structural insights impacting hemophilia B therapy
Bos MH, van Diest RE, Monroe DM
Blood 2024
Protease propeptide structures, mechanisms of activation, and functions
L Boon, E Ugarte-Berzal, J Vandooren, G Opdenakker
Critical Reviews in Biochemistry and Molecular Biology 2020
A candidate activation pathway for coagulation factor VII
TM Misenheimer, KT Kumfer, BE Bates, ER Nettesheim, BS Schwartz
Biochemical Journal 2019
Expression and characterization of a novel human recombinant factor IX molecule with enhanced in vitro and in vivo clotting activity
E Perot, N Enjolras, SL Quellec, A Indalecio, J Girard, C Negrier, Y Dargaud
Thrombosis Research 2015
Incorporation of the factor IX Padua mutation into FIX-Triple improves clotting activity in vitro and in vivo:
CY Kao, SJ Yang, MH Tao, YM Jeng, IS Yu, SW Lin
Thrombosis and Haemostasis 2013
Studies on the mechanism of action of the aptamer BAX499, an Inhibitor of tissue factor pathway inhibitor
JY Chang, P Chantrathammachart, DM Monroe, NS Key
Thrombosis Research 2012
Potent anticoagulant aptamer directed against factor IXa blocks macromolecular substrate interaction
B Sullenger, R Woodruff, DM Monroe
The Journal of biological chemistry 2012
A cleavage-resistant urokinase plasminogen activator receptor exhibits dysregulated cell-surface clearance
EC Nieves, N Manchanda
The Journal of biological chemistry 2010
Generation of a novel factor IX with augmented clotting activities in vitro and in vivo
CN Lin, CY Kao, CH Miao, N Hamaguchi, HL Wu, GY Shi, YL Liu, KA High, SW Lin
Journal of Thrombosis and Haemostasis 2010
FVII Dependent Coagulation Activation in Citrated Plasma by Polymer Hydrogels
BJ Casey, AM Behrens, JR Hess, ZJ Wu, BP Griffith, P Kofinas
Biomacromolecules 2010
Abnormal hemostasis in a knock-in mouse carrying a variant of factor IX with impaired binding to collagen type IV
T Gui, A Reheman, H Ni, PL Gross, F Yin, D Monroe, PE Monahan, DW Stafford
Journal of Thrombosis and Haemostasis 2009
The Factor IX γ-Carboxyglutamic Acid (Gla) Domain Is Involved in Interactions between Factor IX and Factor XIa
A Aktimur, MA Gabriel, D Gailani, JR Toomey
The Journal of biological chemistry 2002
Identification of Functionally Important Residues of the Epidermal Growth Factor-2 Domain of Factor IX by Alanine-scanning Mutagenesis: RESIDUES ASN 89 –GLY 93 ARE CRITICAL FOR BINDING FACTOR VIIIa
YJ Chang, HL Wu, N Hamaguchi, YC Hsu, SW Lin
The Journal of biological chemistry 2002
Pan Vascular Medicine
P Lanzer, EJ Topol
2002
Residues Y179 and H101 of a Hydrophobic Patch of Factor VII Are Involved in Activation by Factor Xa
J Jin, J Chang, DW Stafford, DL Straight
Biochemistry 2001
The Distinct Roles That Gln-192 and Glu-217 of Factor IX Play in Selectivity for Macromolecular Substrates and Inhibitors
YC Hsu, N Hamaguchi, YJ Chang, SW Lin
Biochemistry 2001
Protease Nexin-2/Amyloid β-Protein Precursor Regulates Factor VIIa and the Factor VIIa–Tissue Factor Complex
F Mahdi, A Rehemtulla, WE van Nostrand, SP Bajaj, AH Schmaier
Thrombosis Research 2000
An Arg/Ser Substitution in the Second Epidermal Growth Factor–Like Module of Factor IX Introduces an O-Linked Carbohydrate and Markedly Impairs Activation by Factor XIa and Factor VIIa/Tissue Factor and Catalytic Efficiency of Factor IXa
MS Hertzberg, SL Facey, PJ Hogg
Blood 1999
Changing Residue 338 in Human Factor IX from Arginine to Alanine Causes an Increase in Catalytic Activity
J Chang, J Jin, P Lollar, W Bode, H Brandstetter, N Hamaguchi, DL Straight, DW Stafford
The Journal of biological chemistry 1998
Nitrophorin-2: A Novel Mixed-Type Reversible Specific Inhibitor of the Intrinsic Factor-X Activating Complex
Y Zhang, JM Ribeiro, JA Guimarães, PN Walsh
Biochemistry 1998
Reduced levels of skeletal muscle Na + K + -ATPase in McArdle disease
RG Haller, T Clausen, J Vissing
Neurology 1998
Structural Integrity of the -Carboxyglutamic Acid Domain of Human Blood Coagulation Factor IXa Is Required for Its Binding to Cofactor VIIIa
PJ Larson, SA Stanfield-Oakley, WJ VanDusen, CK Kasper, KJ Smith, DM Monroe, KA High
The Journal of biological chemistry 1996
Protease Nexin-2/Amyloid β-Protein Precursor Inhibits Factor Xa in the Prothrombinase Complex
F Mahdi, WE van Nostrand, AH Schmaier
The Journal of biological chemistry 1995
Cleavage at Arginine 145 in Human Blood Coagulation Factor IX Converts the Zymogen into a Factor VIII Binding Enzyme
PJ Lenting, H Maat, PP Clijsters, MJ Donath, JA van Mourik, K Mertens
The Journal of biological chemistry 1995
Enhanced Plasmin Inhibition by a Reactive Center Lysine Mutant of the Kunitz-type Protease Inhibitor Domain of the Amyloid β-Protein Precursor
WE van Nostrand, AH Schmaier, RS Siegel, SL Wagner, WC Raschke
The Journal of biological chemistry 1995
Expression, purification, and characterization of the Kunitz-type proteinase inhibitor domain of the amyloid β-protein precursor-like protein-2
WE van Nostrand, AH Schmaier, BR Neiditch, RS Siegel, WC Raschke, SS Sisodia, SL Wagner
Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology 1994
Membrane-dependent reactions in blood coagulation: role of the vitamin K-dependent enzyme complexes
M Kalafatis, NA Swords, MD Rand, KG Mann
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1994
The biochemical basis for the apparent defect of soluble mutant tissue factor in enhancing the proteolytic activities of factor VIIa
MM Fiore, PF Neuenschwander, JH Morrissey
The Journal of biological chemistry 1994
Protease nexin-2/amyloid beta protein precursor. A tight-binding inhibitor of coagulation factor IXa
AH Schmaier, LD Dahl, AJ Rozemuller, RA Roos, SL Wagner, R Chung, WE van Nostrand
Journal of Clinical Investigation 1993
Comparison of the behavior of normal factor IX and the factor IX BM variant hilo in the prothrombin time test using tissue factors from bovine, human, and rabbit sources
JB Lefkowitz, DM Monroe, CK Kasper, HR Roberts
American Journal of Hematology 1993
Heparin binding to protein C inhibitor
CW Pratt, FC Church
The Journal of biological chemistry 1992
Blood clotting factor IX Nagoya 3: The molecular defect of zymogen activation caused by an arginine-145 to histidine substitution
K Suehiro, T Miyata, H Takeya, J Takamatsu, H Saito, M Murakawa, T Okamura, Y Niho, S Iwanaga
Thrombosis Research 1990
Proteolytic activation of human factors IX and X by recombinant human factor VIIa: effects of calcium, phospholipids, and tissue factor
Y Komiyama, AH Pedersen, W Kisiel
Biochemistry 1990
Molecular defect (Gla+14----Lys) and its functional consequences in a hereditary factor X deficiency (factor X "Vorarlberg")
HH Watzke, K Lechner, HR Roberts, SV Reddy, DJ Welsch, P Friedman, G Mahr, P Jagadeeswaran, DM Monroe, KA High
The Journal of biological chemistry 1990
Characterization of the functional defect in factor IX Alabama. Evidence for a conformational change due to high affinity calcium binding in the first epidermal growth factor domain
DM McCord, DM Monroe, KJ Smith, HR Roberts
The Journal of biological chemistry 1990
Comparative platelet binding and kinetic studies with normal and variant factor IXa molecules
SS Ahmad, R Rawala-Sheikh, DM Monroe, HR Roberts, PN Walsh
The Journal of biological chemistry 1990
Recombinant human extrinsic pathway inhibitor. Production, isolation, and characterization of its inhibitory activity on tissue factor-initiated coagulation reactions
AH Pedersen, O Nordfang, F Norris, FC Wiberg, PM Christensen, KB Moeller, J Meidahl-Pedersen, TC Beck, K Norris, U Hedner
The Journal of biological chemistry 1990
Defective propeptide processing and abnormal activation underlie the molecular pathology of factor IX Troed-y-Rhiw
MB Liddell, DP Lillicrap, IR Peake, AL Bloom
British Journal of Haematology 1989
Mechanism by which recombinant factor VIIa shortens the aPTT: Activation of factor X in the absence of tissue factor
DS Telgt, BG Macik, DM McCord, DM Monroe, HR Roberts
Thrombosis Research 1989
A moderate form of hemophilia B is caused by a novel mutation in the protease domain of factor IXVancouver
VA Geddes, BF Bonniec, GV Louie, GD Brayer, AR Thompson, RT MacGillivray
The Journal of biological chemistry 1989
Use of p-aminobenzamidine to monitor activation of trypsin-like serine proteases
DM Monroe, GB Sherrill, HR Roberts
Analytical Biochemistry 1988
Comparison of lipid binding and kinetic properties of normal, variant, and .gamma.-carboxyglutamic acid modified human factor IX and factor IXa
ME Jones, MJ Griffith, DM Monroe, HR Roberts, BR Lentz
Biochemistry 1985

← Previous 1 2 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts